2015
MicroRNA Expression and Association with Clinicopathologic Features in Papillary Thyroid Cancer: A Systematic Review
Han P, Weng C, Khawaja H, Nagarajan N, Schneider E, Umbricht C, Witwer K, Zeiger M. MicroRNA Expression and Association with Clinicopathologic Features in Papillary Thyroid Cancer: A Systematic Review. Thyroid 2015, 25: 1322-1329. PMID: 26414548, DOI: 10.1089/thy.2015.0193.Peer-Reviewed Original ResearchConceptsAggressive clinicopathologic featuresPapillary thyroid cancerClinicopathologic featuresThyroid cancerRoutine central lymph node dissectionSystematic reviewCentral lymph node dissectionMiR expression levelsLymph node dissectionLymph node metastasisLarger tumor sizeUseful prognostic markerExpression levelsWeb of ScienceFull-text publicationsNode dissectionLymphovascular invasionDistant metastasisIndependent predictorsNode metastasisAggressive featuresPrognostic significanceProspective studyTumor sizePrognostic marker
2013
Does BRAF V600E Mutation Predict Aggressive Features in Papillary Thyroid Cancer? Results From Four Endocrine Surgery Centers
Li C, Han P, Lee K, Lee L, Fox A, Beninato T, Thiess M, Dy B, Sebo T, Thompson G, Grant C, Giordano T, Gauger P, Doherty G, Fahey T, Bishop J, Eshleman J, Umbricht C, Schneider E, Zeiger M. Does BRAF V600E Mutation Predict Aggressive Features in Papillary Thyroid Cancer? Results From Four Endocrine Surgery Centers. The Journal Of Clinical Endocrinology & Metabolism 2013, 98: 3702-3712. PMID: 23969188, DOI: 10.1210/jc.2013-1584.Peer-Reviewed Original ResearchConceptsCentral lymph node metastasisCentral lymph node dissectionPapillary thyroid cancerClassical variant papillary thyroid cancerRoutine central lymph node dissectionEndocrine surgery centersBRAF mutationsIndependent predictorsMultivariable analysisAggressive featuresBRAF statusSurgery centersThyroid cancerProphylactic central lymph node dissectionBivariate analysisPresence of LNMLymph node dissectionAggressive clinicopathologic featuresTumor-related factorsAmerican Joint CommitteeLymph node metastasisTreatment of patientsBRAF mutation statusBRAF V600E mutationCentral LNM
2012
Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?
Lee K, Li C, Schneider E, Wang Y, Somervell H, Krafft M, Umbricht C, Zeiger M. Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery 2012, 152: 977-983. PMID: 23062653, PMCID: PMC3715093, DOI: 10.1016/j.surg.2012.08.019.Peer-Reviewed Original ResearchConceptsCentral lymph node dissectionLymph node metastasisPapillary thyroid cancerBRAF mutation statusMutation statusBRAF mutationsNode metastasisSurgical managementClinicopathologic featuresThyroid cancerPresence of LNMRoutine central lymph node dissectionMultivariate logistic regression analysisLymph node dissectionAggressive clinicopathologic featuresInstitutional review board approvalLogistic regression analysisFine-needle aspirationFine-needle aspiration samplesReview board approvalNode dissectionTotal thyroidectomyLymphatic invasionChi-square analysisBoard approvalBRAF V600E mutation and Its Association with Clinicopathological Features of Papillary Thyroid Cancer: A Meta-Analysis
Li C, Lee K, Schneider E, Zeiger M. BRAF V600E mutation and Its Association with Clinicopathological Features of Papillary Thyroid Cancer: A Meta-Analysis. The Journal Of Clinical Endocrinology & Metabolism 2012, 97: 4559-4570. PMID: 23055546, PMCID: PMC3513529, DOI: 10.1210/jc.2012-2104.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAmino Acid SubstitutionCarcinomaCarcinoma, PapillaryFemaleGenetic Association StudiesGenetic Predisposition to DiseaseGlutamic AcidHumansLymphatic MetastasisMaleMutation, MissenseProto-Oncogene Proteins B-rafSex CharacteristicsThyroid Cancer, PapillaryThyroid NeoplasmsTumor BurdenValineConceptsLymph node metastasisPapillary thyroid cancerLymph node dissectionTall cell variant papillary thyroid cancerRoutine central lymph node dissectionCentral lymph node dissectionClassic papillary thyroid cancerNode dissectionBRAF V600E mutationClinicopathological featuresAbsence of capsuleTumor sizeMale genderOdds ratioThyroid cancerBRAF mutationsMantel-Haenszel pooled odds ratiosPresence of LNMV600E mutationStudy-specific odds ratiosManagement of patientsPooled odds ratioAggressive clinicopathological featuresImportant clinical decisionsConsecutive patients